The expression profile for MMP-9, TIMP-1, RECK, and miR-338-3p of patients diagnosed with PCa as a diagnostic tool is consistent with the hypothesis that MMP-9 plays a role in the oncogenic process that TIMP-1, RECK, and miR-338-3p act as its inhibitors. Here, MMP9 is linked to posterior cortical atrophy.